2Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571)induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 2000, 96(6): 2246-2253.
3Bhatia R, Holtzl M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylatetreatment. Blood, 2003, 101(12): 4701-4707.
4Rosee PL, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia,2002,16(
5Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosomepositive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 2003, 101 (1):97-
7Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent,Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 2002, 99(1):319 325.
8Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resisitence to imatinib (STI571)therapy. Leukemia, 2002, 16(11): 2190-2196.
9Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol, 2003, 40(1): 50-58.
10Hoover RR, Mahon F-X, Melo JV, et al. Overcoming STI571resistence with the farnesyltransferase inhibitor SCH66366.Blood, 2001, 98(part 1): 617a.
3Gallioli P, Abraham SA, Holyoake TL. Hurdles to- ward a cure for CML:the CML stem cell[J]. Hema- tol Oncol Clin North Ame,2011,25(5) ..951-966.
4Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia[J]. Clin Cancer Res, 2009, 15(24) :7519-7527.
5Reece-Smith AM, MacGoey P, Shah MA, et al. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era[J]. Eur J Surg Oncol,2012,38(6) :484-489.
